Cupps Capital Management’s Pacira BioSciences PCRX Stock Holding History

Cupps Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,100	Closed	-$84K	–	216
2015 Q4	$84K	Buy	+1,100	New	+$62.3K	0.01%	140
2015 Q1	–	Sell	-60,975	Closed	-$5.41M	–	228
2014 Q4	$5.41M	Sell	60,975 -16,330	-21%	-$1.54M	0.48%	69
2014 Q3	$7.49M	Sell	77,305 -5,700	-7%	-$555K	0.69%	55
2014 Q2	$7.62M	Buy	+83,005	New	+$6.32M	0.62%	65

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Cupps Capital Management's PCRX Position: Q1 2016 in Review

Cupps Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 1,100 shares — an estimated $84K sold.

Cupps Capital Management first reported a position in PCRX in Q2 2014 and held it in 4 quarters. The position peaked at $7.62M in Q2 2014. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

Cupps Capital Management reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
Cupps Capital Management sold 1,100 Pacira BioSciences shares in Q1 2016, an estimated $84K.
Cupps Capital Management first reported a position in Pacira BioSciences in Q2 2014 and held it in 4 quarters.
Cupps Capital Management's Pacira BioSciences position peaked at $7.62M in Q2 2014.
180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Cupps Capital Management's 13F filing for Q1 2016, filed 12 May 2016.